Last $34.25 USD
Change Today -0.15 / -0.44%
Volume 424.1K
CBM On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cambrex corp (CBM) Snapshot

Open
$34.01
Previous Close
$34.40
Day High
$34.47
Day Low
$33.90
52 Week High
02/26/15 - $34.93
52 Week Low
10/15/14 - $15.76
Market Cap
1.1B
Average Volume 10 Days
384.8K
EPS TTM
$0.97
Shares Outstanding
31.1M
EX-Date
05/4/07
P/E TM
35.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAMBREX CORP (CBM)

cambrex corp (CBM) Related Bloomberg News

View More Bloomberg News

cambrex corp (CBM) Related Businessweek News

No Related Businessweek News Found

cambrex corp (CBM) Details

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. It serves generic drug companies, and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

1,117 Employees
Last Reported Date: 02/6/15
Founded in 1981

cambrex corp (CBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $412.5K
Managing Director of Cambrex Profarmaco Milan...
Total Annual Compensation: $338.7K
Compensation as of Fiscal Year 2013.

cambrex corp (CBM) Key Developments

Cambrex Announces Expansion of Large Scale API Capacity

Cambrex Corporation announced that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continued growth in demand for the Company's active pharmaceutical ingredient (API) contract manufacturing capabilities is driving the need for more capacity. The Company expects to invest between $45 and $50 million during 2015, including cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016 and is designed to allow Cambrex to quickly and efficiently further expand cGMP capacity, as future growth requires. The new manufacturing facility will initially add a total of 70 cubic meters of glass lined and hastelloy reactors ranging in size from 7m3 to 16m3 along with 6m2 hastelloy filter dryers to provide a flexible, multi-purpose configuration. The facility will be designed to the higher regulatory and safety standards, capable of handling potent APIs at an OEL down to 1 µg/m3 and will significantly increase the Company's cGMP manufacturing capabilities. The facility is also expandable with the ability to add additional capacity on a short timeline. The capacity is being added along with 45,000 square feet of new fully cGMP, temperature and humidity controlled warehouse space.

Cambrex Corporation. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Cambrex Corporation. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company has posted net sales of $128,213,000 against $102,435,000 a year ago. Net revenues were $129,315,000 against $103,036,000 a year ago. Operating profit was $22,578,000 against $16,384,000 a year ago. EBIT was $22,055,000 against $15,077,000 a year ago. Income from continuing operations was $28,258,000 or $0.89 diluted per share against $9,440,000 or $0.30 diluted per share a year ago. Net income was $27,885,000 or $0.88 diluted per share against $8,899,000 or $0.29 diluted per share a year ago. Adjusted operating profit was $28,514,000 against $16,384,000 a year ago. Adjusted EBITDA was $34,425,000 against $22,226,000 a year ago. Adjusted income from continuing operations was $20,358,000 or $0.64 diluted per share against $11,304,000 or $0.36 diluted per share a year ago. Capital expenditures were $13 million. For the year, the company has posted net sales of $371,844,000 against $315,861,000 a year ago. Net revenues were $374,613,000 against $318,176,000 a year ago. Operating profit was $52,298,000 against $49,629,000 a year ago. EBIT was $45,506,000 against $45,007,000 a year ago. Income from continuing operations was $58,133,000 or $1.84 diluted per share against $30,275,000 or $0.98 diluted per share a year ago. Net income was $57,303,000 or $1.81 diluted per share against $25,915,000 or $0.84 diluted per share a year ago. Adjusted operating profit was $58,234,000 against $44,949,000 a year ago. Adjusted EBITDA was $82,060,000 against $67,422,000 a year ago. Adjusted income from continuing operations was $42,132,000 or $1.33 diluted per share against $30,587,000 or $0.99 diluted per share a year ago. Capital expenditures were $31.2 million, which includes $1.3 million of capitalized software recorded in the tangible assets and depreciation was $23.3 million. For the full year, net debt improved by $42 million. For the year, the company expects gross sales increase of 16% - 20%; Adjusted EBITDA to be $101 million - $107 million; Adjusted income from continuing to be $1.62 - $1.75 per share; Capital expenditures to be $80 - $85 million; and effective tax rate to be 33% - 36%. As a result of this high-level investment projected for 2015, the company expects only a moderate reduction in net debt of $5 million to $10 million during 2015.

Cambrex Corporation. to Report Q4, 2014 Results on Feb 06, 2015

Cambrex Corporation. announced that they will report Q4, 2014 results on Feb 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBM:US $34.25 USD -0.15

CBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aceto Corp $21.41 USD +0.06
Albany Molecular Research Inc $16.22 USD +0.05
Biocon Ltd 426.95 INR 0.00
Produits Chimiques Auxiliaires et de Synthese €4.39 EUR +0.15
Siegfried Holding AG SFr.160.00 CHF +0.80
View Industry Companies
 

Industry Analysis

CBM

Industry Average

Valuation CBM Industry Range
Price/Earnings 18.6x
Price/Sales 2.8x
Price/Book 4.2x
Price/Cash Flow 18.6x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMBREX CORP, please visit www.cambrex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.